High permanent plasma adrenaline levels: a marker of adrenal medullary disease in medullary thyroid carcinoma
- 1 February 1991
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 34 (2) , 133-138
- https://doi.org/10.1111/j.1365-2265.1991.tb00283.x
Abstract
Increases in urinary, plasma and tumour adrenaline have been previously observed in MEN II patients with phaeochromocytoma. However, the sensitivity of adrenaline for early detection of adrenal medullary disease has not been accurately evaluated. Twenty-five patients with medullary thyroid carcinoma (MTC) histologically confirmed but without clinical or biological evidence of phaeochromocytoma have been studied. Medullary adrenal status was evaluated by adrenal CT-scan. MIBG scintigraphy, determination of urinary VMA, metanephrines and total catecholamine levels, measurement of nyctohemeral plasma adrenaline or noradrenaline concentrations (every 2 h during 24 h) and clonidine suppression test. Four of the 25 patients had evidence of adrenal medullary disease in view of the coexistence of CT-scan, MIBG scintigraphy and plasma adrenaline abnormalities. Moderate adrenal enlargement (unilateral, n = 3; bilateral, n = 1) was observed on scans together with a high adrenal MIBG uptake (bilateral, n = 4). Among the urinary parameters studied, a minor MN increase was observed in only one of the four patients. Plasma adrenaline levels were significantly (P less than 0.01) different from those of the other 21 patients (mean + SD 115 + 110 pmol/l). This plasma adrenaline increase is reproducible and not suppressed by clonidine. Unilateral adrenalectomy performed in one patient confirmed a phaeochromocytoma and induced normalization of plasma adrenaline levels. In contrast, the plasma noradrenaline levels of the four patients were not statistically different from those of the other 21 patients. These data suggest that persistent high plasma adrenaline levels may be selectively increased in MTC patients together with a moderate adrenal CT-scan enlargement and a high adrenal MIBG uptake, despite a normal urinary excretion of total catecholamines and catecholamines metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 14 references indexed in Scilit:
- The Clinical Outcome of Prospective Screening for Multiple Endocrine Neoplasia Type 2ANew England Journal of Medicine, 1988
- Plasma free and conjugated catecholamines in clinical disordersLife Sciences, 1986
- Clonidine-suppression test in epinephrine secreting pheochromocytoma: report of a caseJournal of Endocrinological Investigation, 1985
- Plasma free and conjugated catecholamines in diagnosis and localisation of pheochromocytomaClinica Chimica Acta; International Journal of Clinical Chemistry, 1983
- Urinary Epinephrine and Norepinephrine Excretion in Patients with Medullary Thyroid Carcinoma and Their RelativesFolia Endocrinologica Japonica, 1982
- The Effects of Age on the Plasma Catecholamine Response to Mental Stress in Man*Journal of Clinical Endocrinology & Metabolism, 1982
- Alters- und belastungsbedingtes Verhalten der PlasmacatecholamineJournal of Molecular Medicine, 1981
- INCREASED SENSITIVITY AND ACCURACY OF PHAEOCHROMOCYTOMA DIAGNOSIS ACHIEVED BY USE OF PLASMA-ADRENALINE ESTIMATIONS AND A PENTOLINIUM-SUPPRESSION TESTThe Lancet, 1981
- Measurement of urinary epinephrine in screening for pheochromocytoma in multiple endocrine neoplasia type IIThe American Journal of Medicine, 1978
- Adrenal Medullary Disease in Multiple Endocrine Neoplasia, Type 2: Pheochromocytoma and Its PrecursorsAmerican Journal of Clinical Pathology, 1976